{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:13:20Z","timestamp":1780632800999,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00415-024-12872-6","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T13:05:14Z","timestamp":1736946314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Differential diagnosis in immune checkpoint inhibitors neurotoxicity"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-0127","authenticated-orcid":false,"given":"Catherine R.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anza","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrang","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Kamiya-Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Tummala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"4","key":"12872_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7722","volume":"5","author":"MZ Farooq","year":"2022","unstructured":"Farooq MZ, Aqeel SB, Lingamaneni P, Pichardo RC, Jawed A, Khalid S et al (2022) Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open 5(4):e227722. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.7722","journal-title":"JAMA Netw Open"},{"issue":"8","key":"12872_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","volume":"22","author":"EC Scott","year":"2023","unstructured":"Scott EC, Baines AC, Gong Y, Moore R Jr, Pamuk GE, Saber H et al (2023) Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat Rev Drug Discov 22(8):625\u2013640. https:\/\/doi.org\/10.1038\/s41573-023-00723-4","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"12872_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/wnl.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J et al (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96(16):754\u2013766. https:\/\/doi.org\/10.1212\/wnl.0000000000011795","journal-title":"Neurology"},{"issue":"3","key":"12872_CR4","doi-asserted-by":"publisher","first-page":"fcad169","DOI":"10.1093\/braincomms\/fcad169","volume":"5","author":"A Farina","year":"2023","unstructured":"Farina A, Birzu C, Elsensohn MH, Picca A, Mu\u00f1iz-Castrillo S, Vogrig A et al (2023) Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun 5(3):fcad169. https:\/\/doi.org\/10.1093\/braincomms\/fcad169","journal-title":"Brain Commun"},{"key":"12872_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004670","author":"BC Tiu","year":"2022","unstructured":"Tiu BC, Zubiri L, Iheke J, Pahalyants V, Theodosakis N, Ugwu-Dike P et al (2022) Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-004670","journal-title":"J Immunother Cancer"},{"issue":"8","key":"12872_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14740338.2021.1915279","volume":"20","author":"JE Lommerts","year":"2021","unstructured":"Lommerts JE, Bekkenk MW, Luiten RM (2021) Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. Expert Opin Drug Saf 20(8):883\u2013888. https:\/\/doi.org\/10.1080\/14740338.2021.1915279","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"12872_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100791","volume":"8","author":"A Boutros","year":"2023","unstructured":"Boutros A, Bottini A, Rossi G, Tanda ET, Spagnolo F, Barletta G et al (2023) Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature. ESMO Open 8(1):100791. https:\/\/doi.org\/10.1016\/j.esmoop.2023.100791","journal-title":"ESMO Open"},{"issue":"5","key":"12872_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/17512433.2023.2211262","volume":"16","author":"R Ruggiero","year":"2023","unstructured":"Ruggiero R, Di Napoli R, Balzano N, Ruggiero D, Riccardi C, Anatriello A et al (2023) Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management. Expert Rev Clin Pharmacol 16(5):423\u2013434. https:\/\/doi.org\/10.1080\/17512433.2023.2211262","journal-title":"Expert Rev Clin Pharmacol"},{"key":"12872_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"issue":"36","key":"12872_CR10","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/jco.21.01440","journal-title":"J Clin Oncol"},{"key":"12872_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000207632","author":"J Pepys","year":"2023","unstructured":"Pepys J, Stoff R, Ramon-Gonen R, Ben-Betzalel G, Grynberg S, Frommer RS et al (2023) Incidence and outcome of neurologic immune-related adverse events associated with immune checkpoint inhibitors in patients with melanoma. Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000207632","journal-title":"Neurology"},{"issue":"Suppl 4","key":"12872_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000540","volume":"4","author":"L Spain","year":"2019","unstructured":"Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S (2019) How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open 4(Suppl 4):e000540. https:\/\/doi.org\/10.1136\/esmoopen-2019-000540","journal-title":"ESMO Open"},{"issue":"9","key":"12872_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jamaneurol.2022.1824","volume":"79","author":"V Damato","year":"2022","unstructured":"Damato V, Berretta A, Ramanathan S, Michael S, Coupe N, Payne M et al (2022) Association between a distinctive autoantibody-associated brainstem sensory syndrome and immune checkpoint inhibitors. JAMA Neurol 79(9):949\u2013951. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1824","journal-title":"JAMA Neurol"},{"issue":"8","key":"12872_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870\u2013881. https:\/\/doi.org\/10.1136\/jnnp-2018-320106","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"16","key":"12872_CR15","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1002\/cncr.32966","volume":"126","author":"S Grover","year":"2020","unstructured":"Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J et al (2020) Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer 126(16):3758\u20133767. https:\/\/doi.org\/10.1002\/cncr.32966","journal-title":"Cancer"},{"issue":"6","key":"12872_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/bjh.18985","volume":"202","author":"S Dasari","year":"2023","unstructured":"Dasari S, Tse W, Wang J (2023) Real-world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors. Br J Haematol 202(6):1205\u20131208. https:\/\/doi.org\/10.1111\/bjh.18985","journal-title":"Br J Haematol"},{"issue":"3","key":"12872_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","volume":"101","author":"L Henze","year":"2022","unstructured":"Henze L, Buhl C, Sandherr M, Cornely OA, Heinz WJ, Khodamoradi Y et al (2022) Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the guidelines of the Infectious diseases working party (AGIHO) of the German society for hematology and medical oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. Ann Hematol 101(3):491\u2013511. https:\/\/doi.org\/10.1007\/s00277-021-04746-y","journal-title":"Ann Hematol"},{"issue":"2","key":"12872_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-011-0609-2","volume":"105","author":"JJ Graber","year":"2011","unstructured":"Graber JJ, Rosenblum MK, DeAngelis LM (2011) Herpes simplex encephalitis in patients with cancer. J Neurooncol 105(2):415\u2013421. https:\/\/doi.org\/10.1007\/s11060-011-0609-2","journal-title":"J Neurooncol"},{"issue":"2","key":"12872_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/COC.0b013e318209aa41","volume":"35","author":"HS Lee","year":"2012","unstructured":"Lee HS, Park JY, Shin SH, Kim SB, Lee JS, Lee A et al (2012) Herpesviridae viral infections after chemotherapy without antiviral prophylaxis in patients with malignant lymphoma: incidence and risk factors. Am J Clin Oncol 35(2):146\u2013150. https:\/\/doi.org\/10.1097\/COC.0b013e318209aa41","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"12872_CR20","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1186\/s12885-019-6444-0","volume":"19","author":"T Sakoh","year":"2019","unstructured":"Sakoh T, Kanzaki M, Miyamoto A, Mochizuki S, Kakumoto T, Sato K et al (2019) Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. BMC Cancer 19(1):1220. https:\/\/doi.org\/10.1186\/s12885-019-6444-0","journal-title":"BMC Cancer"},{"issue":"11","key":"12872_CR21","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/cid\/ciw539","volume":"63","author":"M Del Castillo","year":"2016","unstructured":"Del Castillo M, Romero FA, Arg\u00fcello E, Kyi C, Postow MA, Redelman-Sidi G (2016) The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 63(11):1490\u20131493. https:\/\/doi.org\/10.1093\/cid\/ciw539","journal-title":"Clin Infect Dis"},{"issue":"8","key":"12872_CR22","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.jtho.2019.02.033","volume":"14","author":"Y Watanabe","year":"2019","unstructured":"Watanabe Y, Kikuchi R, Iwai Y, Ito M, Tsukamoto H, Yamazaki K et al (2019) Varicella zoster virus encephalitis mimicking nivolumab-induced autoimmune neuropathy in a patient with lung cancer. J Thorac Oncol 14(8):e163\u2013e165. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.033","journal-title":"J Thorac Oncol"},{"key":"12872_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9040778","author":"T Murata","year":"2021","unstructured":"Murata T (2021) Human herpesvirus and the immune checkpoint PD-1\/PD-L1 pathway: disorders and strategies for survival. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms9040778","journal-title":"Microorganisms"},{"issue":"1","key":"12872_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4049\/jimmunol.0902373","volume":"184","author":"GM Frank","year":"2010","unstructured":"Frank GM, Lepisto AJ, Freeman ML, Sheridan BS, Cherpes TL, Hendricks RL (2010) Early CD4(+) T cell help prevents partial CD8(+) T cell exhaustion and promotes maintenance of herpes simplex virus 1 latency. J Immunol 184(1):277\u2013286. https:\/\/doi.org\/10.4049\/jimmunol.0902373","journal-title":"J Immunol"},{"issue":"3","key":"12872_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaneurol.2013.4580","volume":"71","author":"A DeSena","year":"2014","unstructured":"DeSena A, Graves D, Warnack W, Greenberg BM (2014) Herpes simplex encephalitis as a potential cause of Anti\u2013N-Methyl-d-aspartate receptor antibody encephalitis: report of 2 cases. JAMA Neurol 71(3):344\u2013346. https:\/\/doi.org\/10.1001\/jamaneurol.2013.4580","journal-title":"JAMA Neurol"},{"issue":"2","key":"12872_CR26","doi-asserted-by":"publisher","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","volume":"2","author":"S Shelly","year":"2020","unstructured":"Shelly S, Triplett JD, Pinto MV, Milone M, Diehn FE, Zekeridou A et al (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2(2):fcaa181. https:\/\/doi.org\/10.1093\/braincomms\/fcaa181","journal-title":"Brain Commun"},{"issue":"3","key":"12872_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jdcr.2018.11.017","volume":"5","author":"J Lu","year":"2019","unstructured":"Lu J, Thuraisingam T, Chergui M, Nguyen K (2019) Nivolumab-associated DRESS syndrome: a case report. JAAD Case Rep 5(3):216\u2013218. https:\/\/doi.org\/10.1016\/j.jdcr.2018.11.017","journal-title":"JAAD Case Rep"},{"issue":"3","key":"12872_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/cmr.0000000000000326","volume":"27","author":"S Mirza","year":"2017","unstructured":"Mirza S, Hill E, Ludlow SP, Nanjappa S (2017) Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res 27(3):271\u2013273. https:\/\/doi.org\/10.1097\/cmr.0000000000000326","journal-title":"Melanoma Res"},{"key":"12872_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002879","author":"L Ai","year":"2021","unstructured":"Ai L, Gao J, Zhao S, Li Q, Cui YH, Liu Q et al (2021) Nivolumab-associated DRESS in a genetic susceptible individual. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002879","journal-title":"J Immunother Cancer"},{"issue":"6","key":"12872_CR30","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.anai.2017.03.007","volume":"118","author":"J Massey","year":"2017","unstructured":"Massey J, Kumar K, Ng K, Yun J, Fernando S (2017) Skeletal myositis as the sole feature of relapsing drug reaction with eosinophilia and systemic symptoms syndrome. Ann Allergy Asthma Immunol 118(6):726\u2013728. https:\/\/doi.org\/10.1016\/j.anai.2017.03.007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"12872_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3346\/jkms.2008.23.3.521","volume":"23","author":"JH Lee","year":"2008","unstructured":"Lee JH, Park HK, Heo J, Kim TO, Kim GH, Kang DH et al (2008) Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci 23(3):521\u2013525. https:\/\/doi.org\/10.3346\/jkms.2008.23.3.521","journal-title":"J Korean Med Sci"},{"issue":"3","key":"12872_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/bor.0000000000000935","volume":"35","author":"M Defoe","year":"2023","unstructured":"Defoe M, Bermas BL (2023) Rheumatologic immune checkpoint inhibitor-related adverse events. Curr Opin Rheumatol 35(3):141\u2013148. https:\/\/doi.org\/10.1097\/bor.0000000000000935","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"12872_CR33","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellner","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X et al (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17(8):1019\u20131032. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03066.x","journal-title":"Eur J Neurol"},{"issue":"7","key":"12872_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M et al (2021) Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry 92(7):757\u2013768. https:\/\/doi.org\/10.1136\/jnnp-2020-325300","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"12872_CR35","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1468-1331.2006.01266.x","volume":"13","author":"CA Vedeler","year":"2006","unstructured":"Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK et al (2006) Management of paraneoplastic neurological syndromes: report of an EFNS task force. Eur J Neurol 13(7):682\u2013690. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01266.x","journal-title":"Eur J Neurol"},{"key":"12872_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001088","author":"FS Thaler","year":"2021","unstructured":"Thaler FS, Zimmermann L, Kammermeier S, Strippel C, Ringelstein M, Kraft A et al (2021) Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000001088","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"12872_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangu\u00e9 T, Glaser C, Iizuka T et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157\u2013165. https:\/\/doi.org\/10.1016\/s1474-4422(12)70310-1","journal-title":"Lancet Neurol"},{"key":"12872_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/tcrm.S223468","volume":"16","author":"S Si","year":"2020","unstructured":"Si S, Teachey DT (2020) Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag 16:705\u2013714. https:\/\/doi.org\/10.2147\/tcrm.S223468","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"12872_CR39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","volume":"70","author":"BC Kieseier","year":"2013","unstructured":"Kieseier BC, St\u00fcve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK et al (2013) Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 70(3):390\u2013393. https:\/\/doi.org\/10.1001\/jamaneurol.2013.668","journal-title":"JAMA Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12872-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12872-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12872-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:41:16Z","timestamp":1739637676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12872-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["12872"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12872-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"116"}}